What is Pacific Biosciences of California Gross Margin %?
Pacific Biosciences of CaliforniaPACB +11.11%53 Gross Margin % is 34.54% as of Mar. 2026, which is 8% below its 10-year median of 37.56. GuruFocus rates PACB with a GF Score™ of 53/100 and a GF Value™ of $1.62 (Fairly Valued). The stock has 7 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Pacific Biosciences of California ranks worse than 71.8% on this metric.
Pacific Biosciences of California (NAS:PACB) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Pacific Biosciences of California had a gross margin of 34.54% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Pacific Biosciences of California Gross Margin % Related Terms
Pacific Biosciences of California Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacific Biosciences of California Gross Margin % Chart
PACB vs CATX, LAB, KIDS: Gross Margin % Comparison
For the Medical Devices subindustry, Pacific Biosciences of California's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacific Biosciences of California Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Pacific Biosciences of California's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Pacific Biosciences of California (PACB) has a Gross Margin % of 34.54% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Pacific Biosciences of California and its competitors. This is near median its historical median of 37.56. Over the past decade, Pacific Biosciences of California's Gross Margin % has ranged from 24.21 to 48.68. According to the industry distribution chart, Pacific Biosciences of California ranks #578 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 71.8%.
Is Pacific Biosciences of California's Gross Margin % too high?
Pacific Biosciences of California's current Gross Margin % of 34.54% is near median its 10-year median of 37.56. Over the past 10 years, this metric has ranged from a low of 24.21 to a high of 48.68. The Medical Devices & Instruments industry median Gross Margin % is 52.07. Pacific Biosciences of California's value of 34.54% is 33.7% below this industry median. Based on the distribution chart, Pacific Biosciences of California ranks #578 out of 805 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Pacific Biosciences of California has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pacific Biosciences of California's Gross Margin % compare to CATX and LAB?
According to the Medical Devices & Instruments industry distribution chart, Pacific Biosciences of California ranks #578 out of 805 companies for Gross Margin %. This places Pacific Biosciences of California in the lower half of its industry. The industry median Gross Margin % is 52.07. Pacific Biosciences of California's value of 34.54% is 33.7% below this benchmark. Historically, Pacific Biosciences of California's own Gross Margin % has ranged from 24.21 to 48.68 over the past decade. While the company's 10-year median is 37.56 vs. the industry median of 52.07, Pacific Biosciences of California has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.07, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacific Biosciences of California's current Gross Margin % of 34.54% is 33.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Pacific Biosciences of California and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacific Biosciences of California's current Gross Margin % is 34.54%, which is near median its own 10-year median of 37.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Biosciences of California stock overvalued right now?
Based on GuruFocus' analysis, Pacific Biosciences of California (PACB) is currently considered Fairly Valued. The stock's GF Value™ is $1.62, compared to a current price of $1.60 — trading 1.2% below its estimated fair value. The current Gross Margin % is 34.54%, which is near median its 10-year median of 37.56 and 33.7% below the Medical Devices & Instruments industry median of 52.07. Pacific Biosciences of California's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Pacific Biosciences of California (PACB), the current Gross Margin % is 34.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacific Biosciences of California (PACB) Overvalued in 2026?
Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be undervalued.
The current stock price of $1.60 is trading 1.2% below its estimated GF Value™ of $1.62.
GuruFocus considers Pacific Biosciences of California to be Fairly Valued.
Key valuation signals for PACB:
Gross Margin %: 34.54% (near median its 10-year median of 37.56)
GF Value™: $1.62 vs. price of $1.60 (1.2% below fair value)
Industry Position: 33.7% below the Medical Devices & Instruments median (#578 of 805)
No single metric tells the full story. See the PACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacific Biosciences of California Business Description
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
53GF Score
Get the complete analysis for PACB
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PACB has been successfully added to your 
